|
| Drugs | Dose | Authors (year) | Number of patients | Type of study | Outcomes |
|
| 5-ASA/SSZ | 2.4–4 g/day | Jung et al.
(2012) | 143/292 | Retrospective cohort study | Positive effect in maintaining remission |
|
| THD | 2-3 mg/kg/day | Yasui et al.
(2008)
| 7 | Case series | Dramatic improvement in clinical symptoms |
| — | Lee et al.
(2010) | 4 | Case series | 3/4 patients had a clinical improvement and all discontinued steroid therapy |
|
THD/IFX/ADA/
ETA | THD 50–100 mg/day
IFX 5 mg/kg every 8 weeks
ADA 160 mg at week 0 and 80 mg at week 2, followed by 40 mg every other week
ETA 25 mg twice a week | Hatemi et al. (2015) | 13/64 | Observational study | Remission obtained with TNF-α antagonists and/or THD in about 75% of cases. |
|
| AZA or 6-MP | AZA 2–2.5 mg/kg/day
6-MP 0.5–1.5 mg/kg/day | Jung et al.
(2012) | 67/272 | Retrospective study | Relative good effect for maintenance of remission |
|
AZA or 6-MP
vs
5-ASA | AZA 2–2.5 mg/kg/day
or
6-MP 1–1.5 mg/kg/day
vs
5-ASA 3-4 g/day | Lee et al.
(2015) | 77 | Retrospective observational study | The rates of reoperation, readmission, and death were not significantly different between the 5-ASA and thiopurine groups |
|
| MTX + IFX | MTX -
FX 3–5 mg/kg every 8 weeks | Iwata et al.
(2011) | 10 | Observational study | Long-term alleviation of entero-BD and excellent tolerability with combination of IFX and MTX |
|
| INF- | 6 × 106 IU per day for 14 days | Grimbacher et al.
(1997) | 1 | Case report | Complete remission of Behçet’s retinal infiltrates and BD-related colitis |
| 3 × 106 IU/day 3 times/week increased to 6 × 106 IU/day 3 times/week | Monastirli et al.
(2010) | 1 | Case report | Complete remission of all clinical manifestations
|
|
| IVIg | 400 mg/kg/day for 5 days per month | Cantarini et al.
(2016) | 1/4 | Case series | Complete disease remission of gastrointestinal, manifestations |
|
| IFX | — | Ideguchi et al.
(2014) | 7/43 | Retrospective observational study | Good response in two patients, remission in one, partial response in two, and unchanged GI lesions in two patients |
| 5 mg/kg/every 8 weeks | Lee et al.
(2013) | 28 | Multicenter retrospective study | IFX efficacy for patients with moderate-to-severe intestinal BD |
| 5 mg/kg every 8 weeks | Kinoshita et al.
(2013) | 15/43 | Retrospective cohort study | Acceptable efficacy of IFX in BD patients refractory to conventional treatments |
| 5 mg/kg every 8 weeks | Hibi et al.
(2016) | 11/18 | Open-label study | IFX efficacy in the treatment of intestinal BD |
|
| ADA | 160 mg at week 0 and 80 mg at week 2, followed by 40 mg every other week | Tanida et al.
(2015) | 20 | Multicenter, open-label, uncontrolled study | ADA effectiveness in inducing and maintaining clinical improvement and remission in patients with intestinal BD |
| 160 mg at week 0 and 80 mg at week 2, followed by 40 mg every other week | Tanida et al.
(2016) | 8 | Retrospective observational study | Long-term efficacy and safety of ADA for the treatment of intestinal BD in the clinical setting |
|
| ETA | 25 mg twice a week | Ma et al.
(2014) | 19/35 | Observational study | The relapse rate for etanercept therapy was reduced significantly when compared with conventional therapy |
|
| ANA | 100 mg/day
2 mg/kg/day increased to 2.5 mg/kg/day | Cantarini et al.
(2013) | 3/9 | Case series | Complete resolution of abdominal pain in two patients,
relapse in one patient |
|
| CANA | 150 mg every 8 weeks
150 mg every six weeks | Vitale et al.
(2013) | 2/3 | Case series | Complete resolution of abdominal pain |
|
| TCZ | 8 mg/kg/ every 4 weeks | Deroux et al.
(2015) | 3/4 | Case series | Less effective for arthralgia and abdominal pain |
|
